Jagsonpal Pharmaceuticals: SEBI Takeover Disclosure filed under Regulation 31(4)
Jagsonpal Pharmaceuticals Limited, a publicly listed pharmaceutical company, has filed a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with the NSE. This filing is a mandatory disclosure requirement when a person or group proposes to acquire shares that would result in substantial control or when crossing the 25% shareholding threshold. The precise acquirer identity, consideration structure, and target shareholding percentage are not disclosed in the NSE filing header.
Why it mattersRegulation 31(4) disclosure signals either a pre-bid announcement by an acquirer or a material shareholder crossing the 25% threshold; the filing initiates the formal takeover timeline under SEBI SAST, requiring open offer mechanics and board approval scrutiny.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives – Jagsonpal Pharmaceuticals disclosure filing · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026